Serologicals Announces Stockholder Approval of Merger
2006年7月13日 - 12:21AM
ビジネスワイヤ(英語)
Serologicals Corporation (NASDAQ:SERO) announced today that its
stockholders overwhelmingly approved the proposed acquisition of
Serologicals by Millipore Corporation at a special stockholders'
meeting held today in New York City. Harold W. Ingalls, the Vice
President, Finance and Chief Financial Officer of Serologicals,
stated that 28,172,696 shares of Serologicals Common Stock were
present in person or by proxy at the special meeting, representing
approximately 82.4% of the shares outstanding on the record date
for the special meeting. Holders of 28,143,760 shares, or
approximately 82.3% of the shares outstanding on the record date,
voted in favor of the adoption of the Agreement and Plan of Merger
among Serologicals, Millipore and Millipore's acquisition
subsidiary. David A. Dodd, the President and Chief Executive
Officer of Serologicals, commented regarding the special meeting,
stating "I am very pleased that our shareowners so resoundingly
approved our transaction with Millipore. This combination of two
outstanding companies will create a company with leading products
in many important areas of the life sciences tools industry. The
tremendous increase in value of Serologicals over the past several
years is a tribute to the focus on value creation by our
outstanding employees worldwide. It has been a great pleasure
working with and representing this team. Millipore is an
outstanding organization and we wish them the very best of
continued success." Serologicals Corporation, headquartered in
Atlanta, Georgia, is a global provider of biological products and
enabling technologies, which are essential for the research,
development and manufacturing of biologically based life science
products. The Company's products and technologies are used in a
wide variety of innovative applications within the areas of
oncology, hematology, immunology, cardiology and infectious
diseases, as well as in the study of molecular biology.
Serologicals has approximately 1,000 employees worldwide, and its
shares are traded on the NASDAQ national stock market under the
symbol SERO. On April 25, 2006, Serologicals entered into an
Agreement and Plan of Merger with Millipore Corporation and one of
its wholly-owned subsidiaries, pursuant to which Millipore
Corporation will acquire Serologicals. This release contains
certain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those expressed in any
forward-looking statements, including general industry and market
conditions. Additional information concerning these and other risks
and uncertainties is outlined in Serologicals' filings with the
Securities and Exchange Commission, including the Annual Report on
Form 10-K filed with the Securities and Exchange Commission on
March 16, 2006. This report is available online at
http://www.sec.gov. You should not place undue reliance on
forward-looking statements, since the statements speak only as of
the date that they are made, and Serologicals undertakes no
obligation to update these statements based on events that may
occur after the date of this press release. Serologicals is a
registered trademark of Serologicals Royalty Company.
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 5 2024 まで 6 2024
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Serologicals (MM) (ナスダック市場): 0 recent articles
その他のSerologicals Corporationニュース記事